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Vitamin D sufficiency in pregnancy
Better evidence is required to establish optimal levels and need for supplementation
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One year ago, the chief medical officers of the United Kingdom
recommended that “All pregnant and breastfeeding women
should take a daily supplement containing 10 μg (400 IU) of
vitamin D,” to counter the high prevalence of vitamin D
deficiency in pregnant women. This was aimed at reducing the
associated consequences of deficiency, such as rickets in
children and osteomalacia in adults.1
In a linked meta-analysis (doi:10.1136/bmj.f1169), Aghajafari
and colleagues look beyond bone health to other adverse health
outcomes for mother and baby.2 Previous systematic reviews
have highlighted challenges in combining data from different
studies, including diverse definitions of vitamin D deficiency,
variations in vitamin D assays used, use of non-representative
samples, and varying study designs and study quality.3 4
A review published in 2011 found insufficient high quality
studies to conduct quantitative meta-analysis3; in the qualitative
review the evidence was inconsistent. In a subsequent review,
rigorous assessment of study quality resulted in quantitative
meta-analyses of only two observational studies and five
randomised controlled trials, with additional studies reviewed
qualitatively.4 Combined data from trials suggested that bolus
high dose vitamin D supplementation (but not daily dosing) was
associated with reduced risk of low birth weight (risk ratio 0.40;
95% confidence interval 0.23 to 0.71). Combined trial data
found no significant protective effect of vitamin D
supplementation on the outcome small for gestational age (0.77,
0.35 to 1.66), although observational studies supported a
protective effect. Results for maternal outcomes were
inconsistent. In a 2012 Cochrane systematic review,
meta-analysis of three trials of daily vitamin D supplementation
during pregnancy found a reduced risk of low birth weight (0.48,
0.23 to 1.01), although this was not significant.5
In a recent combined analysis of two randomised controlled
trials, higher vitamin D (measured as serum concentration of
25-hydroxyvitamin D; 25-OHD) at delivery was associated with
a significantly (P<0.006) decreased risk of “comorbidities of
pregnancy.” Comorbidities were gestational diabetes,
hypertension, infection, bacterial vaginosis, and preterm birth
without pre-eclampsia, but the study did not have enough power
to analyse individual outcomes.6
Meta-analysis overcomes the problems of small sample sizes
and insufficient power. But challenges arise in combining data
from studies of different designs, inclusion and exclusion
criteria, and definitions of exposure and outcome. Aghajafari
and colleagues’ review contains no primary data from vitamin
D intervention studies.2 Only one trial was considered, but was
excluded from analysis. The largest effect sizes derive from
case-control studies, some with minimal or no adjustment for
confounding; comparisons of extreme groups (such as <50 v
>75 mmol/L), so that data from most of the sample (the middle
group) are omitted7; and blood sampling after “disease” onset.
Serum 25-OHD concentration is labile. It depends on recent
intake of vitamin D and sun exposure, both of which may
change, andmay even be affected by preclinical disease (disease
induced vitamin D deficiency).
Gestational age at sampling is also relevant to causal
interpretations if low vitamin D status at late sampling is linked
to outcomes that are usually associated with earlier gestational
onset. Aghajafari and colleagues found that “vitamin D
deficiency”—variously defined and measured at different
gestational ages—is adverse for maternal and infant health. If
lower vitamin D status causes these outcomes in a linear way,
more severe deficiency (<50 nmol/L) would be expected to have
a stronger effect than less severe deficiency (<75 nmol/L). The
opposite effect seems to occur for pre-eclampsia.2
Despite these challenges to interpreting the evidence, these
studies have clear clinical implications. In 2010 the US Institute
of Medicine recommended that a serum concentration of
25-OHD of 50 nmol/L or more should be considered sufficient
for bone health.8 Although optimal maternal 25-OHD levels at
different gestational times are not known, levels below 50
nmol/L are common during pregnancy, particularly in
populations at high latitudes and in specific subpopulations.
Evidence of a causal association between vitamin D deficiency
and some maternal and neonatal outcomes is insufficient, but
the evidence for bone health is clear cut. The findings of this
meta-analysis support a goal of vitamin D sufficiency for all
pregnant women.2 Supplements, diet, and sunlight exposure all
influence 25-OHD levels and should be used together, with
care, because U shaped dose-response curves are reported for
robyn.lucas@anu.edu.au
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f1675 doi: 10.1136/bmj.f1675 (Published 27 March 2013) Page 1 of 2
Editorials
EDITORIALS
a range of health outcomes, including small for gestational age,9
with disease risk increasing at both low and high 25-OHD levels.
Most studies are undertaken in developed countries. Yet Asian
and African countries have higher infant mortality and represent
half of the global population. Where it has been measured,
vitamin D deficiency is common in these countries, under the
combined influences of darker skin, cultural practices that limit
sun exposure, and, in some locations, urban air pollution
blocking ultraviolet radiation. For example, median 25-OHD
levels of pregnant women living in Beijing were only 26
nmol/L.10 If there is a causal association between vitamin D
deficiency and adverse maternal and neonatal outcomes, gains
from ensuring sufficiency may be great in these countries.
Current evidence on vitamin D status and neonatal and
pregnancy health derives largely from observational studies,
small trials, low doses of vitamin D supplementation, unclear
study processes of randomisation and blinding, or low
adherence. In their editorial, Harvey and Cooper called for large
well designed randomised controlled trials to clarify the causal
association between vitamin D supplementation and health.11
This is particularly needed to delineate the importance of vitamin
D in pregnancy, with its potentially lifelong effects on the health
of offspring.12
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